CGNNT(SZ:000881) Xin Lang Cai Jing·2025-09-01 12:33Core Viewpoint - The performance briefing held by China General Nuclear Power Corporation (CGN) highlighted the progress of various projects, including the Huaxi proton medical project and the development of new products, while addressing investor concerns about the company's future growth and profitability [1] Group 1: Project Updates - The Huaxi proton medical project has completed equipment production but is not expected to finish acceptance testing within the year due to site readiness issues [1] - Proton therapy order business is facing delays as most public hospitals have not yet entered the procurement phase due to funding and construction challenges [1] - The company is actively tracking demand and communicating with potential hospitals to secure orders [1] Group 2: Product Development - The subsidiary Juner is developing a special PEEK product for applications in electronics, aerospace, and machinery, but it has not yet generated revenue [1] - The high-performance silicon photomultiplier packaging production line is expected to reach mass production conditions in the first half of 2025, with ongoing market development and initial sales orders [1] Group 3: Financial and Strategic Outlook - Revenue from the nuclear power sector accounts for less than 10% of the company's total revenue [1] - The company aims to achieve profitability in 2025 through cost reduction, product transformation, innovation enhancement, and deepening reforms [1] - There are currently no risks of delisting or other risk warnings for the company [1] Group 4: Corporate Governance and Future Plans - The company has no plans for a private placement at this time but will disclose any future plans as required [1] - Emphasis is placed on market expansion through product-centric strategies and active engagement with stakeholders [1] - The company is committed to embracing artificial intelligence to enhance productivity and drive business development [1]